Sichuan Goldstone Asia Pharmaceutical Inc. (SHE:300434)
10.52
-0.12 (-1.13%)
Feb 13, 2026, 3:04 PM CST
SHE:300434 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,018 | 1,066 | 1,171 | 1,200 | 1,006 | 734.16 |
Other Revenue | 36.05 | 36.05 | 38.09 | 42.79 | 47.74 | 43.14 |
| 1,054 | 1,102 | 1,209 | 1,243 | 1,054 | 777.3 | |
Revenue Growth (YoY) | -7.43% | -8.84% | -2.69% | 17.95% | 35.53% | -22.70% |
Cost of Revenue | 440.07 | 473.18 | 467.99 | 480.74 | 459.56 | 359.85 |
Gross Profit | 614.09 | 629.17 | 741.21 | 761.87 | 593.94 | 417.45 |
Selling, General & Admin | 390.19 | 430.14 | 429.02 | 421.07 | 419.15 | 375.19 |
Research & Development | 58.03 | 50 | 50.01 | 39.18 | 37.45 | 27.84 |
Other Operating Expenses | 32.22 | 20.1 | 22.45 | 18.74 | 17.64 | 17.02 |
Operating Expenses | 478.48 | 500.79 | 500.6 | 481.06 | 478.49 | 425.08 |
Operating Income | 135.61 | 128.38 | 240.61 | 280.8 | 115.45 | -7.63 |
Interest Expense | -1.09 | -1.32 | -0.67 | -0.46 | -0.02 | -0.17 |
Interest & Investment Income | 4.74 | 5.34 | 12.09 | 2.74 | 2.97 | 4.32 |
Currency Exchange Gain (Loss) | 0.61 | 0.61 | 0.42 | 1.38 | -0.18 | -1.01 |
Other Non Operating Income (Expenses) | 1.72 | -3.89 | 3.28 | -7.91 | -0.46 | -0.17 |
EBT Excluding Unusual Items | 141.59 | 129.12 | 255.73 | 276.56 | 117.77 | -4.66 |
Impairment of Goodwill | - | - | -67.51 | - | -23.17 | -668.75 |
Gain (Loss) on Sale of Investments | -10.4 | -11.35 | -18.43 | -11.97 | -9.67 | -1.57 |
Gain (Loss) on Sale of Assets | 0.04 | -0.02 | 0.25 | 17.77 | -0 | -0.04 |
Asset Writedown | -4.15 | -4.87 | -0.78 | -1.4 | -2.72 | -0.05 |
Other Unusual Items | 25.29 | 9.78 | 7.76 | 9.58 | 11.34 | 9.97 |
Pretax Income | 152.37 | 122.66 | 177.02 | 290.54 | 93.54 | -665.09 |
Income Tax Expense | 24.74 | 34.1 | 56.31 | 77.49 | 27.43 | 19.38 |
Earnings From Continuing Operations | 127.63 | 88.56 | 120.71 | 213.05 | 66.1 | -684.47 |
Minority Interest in Earnings | 2.77 | 3.2 | 5.49 | 5.74 | 0.38 | -3.19 |
Net Income | 130.4 | 91.76 | 126.2 | 218.79 | 66.48 | -687.66 |
Net Income to Common | 130.4 | 91.76 | 126.2 | 218.79 | 66.48 | -687.66 |
Net Income Growth | 186.30% | -27.29% | -42.32% | 229.10% | - | - |
Shares Outstanding (Basic) | 390 | 399 | 407 | 405 | 391 | 402 |
Shares Outstanding (Diluted) | 390 | 399 | 407 | 405 | 391 | 402 |
Shares Change (YoY) | -7.40% | -2.00% | 0.48% | 3.60% | -2.75% | 0.26% |
EPS (Basic) | 0.33 | 0.23 | 0.31 | 0.54 | 0.17 | -1.71 |
EPS (Diluted) | 0.33 | 0.23 | 0.31 | 0.54 | 0.17 | -1.71 |
EPS Growth | 209.18% | -25.81% | -42.59% | 217.65% | - | - |
Free Cash Flow | 133.6 | 85.23 | 85.04 | 268.89 | 51.03 | 97.91 |
Free Cash Flow Per Share | 0.34 | 0.21 | 0.21 | 0.66 | 0.13 | 0.24 |
Dividend Per Share | 0.069 | 0.069 | 0.110 | - | - | - |
Dividend Growth | -37.27% | -37.27% | - | - | - | - |
Gross Margin | 58.25% | 57.07% | 61.30% | 61.31% | 56.38% | 53.71% |
Operating Margin | 12.86% | 11.65% | 19.90% | 22.60% | 10.96% | -0.98% |
Profit Margin | 12.37% | 8.32% | 10.44% | 17.61% | 6.31% | -88.47% |
Free Cash Flow Margin | 12.67% | 7.73% | 7.03% | 21.64% | 4.84% | 12.60% |
EBITDA | 243.82 | 230.38 | 334.33 | 371.87 | 202.41 | 78.44 |
EBITDA Margin | 23.13% | 20.90% | 27.65% | 29.93% | 19.21% | 10.09% |
D&A For EBITDA | 108.21 | 102 | 93.72 | 91.06 | 86.96 | 86.07 |
EBIT | 135.61 | 128.38 | 240.61 | 280.8 | 115.45 | -7.63 |
EBIT Margin | 12.86% | 11.65% | 19.90% | 22.60% | 10.96% | -0.98% |
Effective Tax Rate | 16.24% | 27.80% | 31.81% | 26.67% | 29.33% | - |
Revenue as Reported | 1,054 | 1,102 | 1,209 | 1,243 | 1,054 | 777.3 |
Advertising Expenses | - | 69.57 | 74.99 | 59.7 | 69.59 | 51.49 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.